BridgeBio Lands $2 Billion Licensing and Development Deal for Infigratinib

Palo Alto, Calif.-based BridgeBio Pharma has struck a $2 billion-plus collaboration deal with Switzerland’s Helsinn Group to further develop infigratinib, BridgeBio’s investigational oncology drug.

Per the deal, BridgeBio is eligible for $2 billion in upfront, regulatory and commercial milestones payments, in addition to royalties on sales made by the Helsinn Group. BridgeBio’s affiliate QED Therapeutics has led the development of the oral therapy so far for treatment for bile duct cancer, urinary tract and bladder cancer and other cancers caused by FGFR gene mutations.

The FDA has given the drug a Priority Review designation and is assessing it under the Real-Time Oncology Review pilot program.